We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00648037
First Posted: April 1, 2008
Last Update Posted: February 1, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
Results First Submitted: October 20, 2015  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Hodgkin's Disease
Leukemia
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma
Intervention: Drug: Rituximab

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Rituximab Prophylaxis in TCD Unrelated or HLA Mismatched HSCT To determine the safety of Rituximab prophylaxis in patients following TCD unrelated or HLA mismatched related HSCT

Participant Flow:   Overall Study
    Rituximab Prophylaxis in TCD Unrelated or HLA Mismatched HSCT
STARTED   26 
COMPLETED   10 
NOT COMPLETED   16 
Not Treated                1 
Withdrawal by Subject                1 
Adverse Event                11 
Relapse                2 
Other                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Rituximab Prophylaxis in TCD Unrelated or HLA Mismatched HSCT To determine the safety of Rituximab prophylaxis in patients following TCD unrelated or HLA mismatched related HSCT

Baseline Measures
   Rituximab Prophylaxis in TCD Unrelated or HLA Mismatched HSCT 
Overall Participants Analyzed 
[Units: Participants]
 26 
Age 
[Units: Participants]
 
<=18 years   9 
Between 18 and 65 years   16 
>=65 years   1 
Gender 
[Units: Participants]
 
Female   9 
Male   17 


  Outcome Measures

1.  Primary:   Safety of Rituximab Prophylaxis   [ Time Frame: 3 months post transplant ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Papadopoulos, Esperanza, MD (Attending)
Organization: Memorial Sloan Kettering Cancer Center
phone: +1212-639-8276
e-mail: papadope@mskcc.org



Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00648037     History of Changes
Other Study ID Numbers: 01-118
First Submitted: March 27, 2008
First Posted: April 1, 2008
Results First Submitted: October 20, 2015
Results First Posted: February 1, 2016
Last Update Posted: February 1, 2016